Mirikizumab Pharmacokinetics and Exposure‐Response in Patients With Moderately‐To‐Severely Active Crohn's Disease: Results From Two Randomized Studies

ABSTRACT Mirikizumab is a humanized anti–interleukin‐23‐p19 monoclonal antibody approved for both moderately‐to‐severely active ulcerative colitis and moderately‐to‐severely active Crohn's disease (CD). We characterized pharmacokinetics (PK) and exposure‐response (ER) of mirikizumab in relation...

Full description

Saved in:
Bibliographic Details
Main Authors: Laiyi Chua, Yuki Otani, Zhantao Lin, Stuart Friedrich, Frederick Durand, Xin Cindy Zhang
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Clinical and Translational Science
Subjects:
Online Access:https://doi.org/10.1111/cts.70320
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849227187341754368
author Laiyi Chua
Yuki Otani
Zhantao Lin
Stuart Friedrich
Frederick Durand
Xin Cindy Zhang
author_facet Laiyi Chua
Yuki Otani
Zhantao Lin
Stuart Friedrich
Frederick Durand
Xin Cindy Zhang
author_sort Laiyi Chua
collection DOAJ
description ABSTRACT Mirikizumab is a humanized anti–interleukin‐23‐p19 monoclonal antibody approved for both moderately‐to‐severely active ulcerative colitis and moderately‐to‐severely active Crohn's disease (CD). We characterized pharmacokinetics (PK) and exposure‐response (ER) of mirikizumab in relation to efficacy and safety in CD using data from randomized phase 2 SERENITY (NCT02891226) and phase 3 VIVID‐1 (NCT03926130) trials. Patients received 12‐week mirikizumab induction (200, 600, or 1000 mg [SERENITY] or 900 mg [VIVID‐1] intravenously [IV]) or placebo, every 4 weeks (Q4W), then maintenance (200, 600, or 1000 mg IV [SERENITY], 300 mg subcutaneously (SC) [SERENITY and VIVID‐1], or placebo, Q4W) to Week 52. PK and ER for efficacy were analyzed using population PK and logistic regression models for Weeks 12 and 52 endpoints, respectively, and included analyses of covariate effects. Mirikizumab PK was best described by a two‐compartment model, with first‐order absorption for SC maintenance doses. Body weight, body mass index, serum albumin concentration, C‐reactive protein, and disease severity had statistically significant effects on PK, while body weight and disease severity affected ER; these effects were not considered clinically relevant. Efficacy results of 900 mg mirikizumab in VIVID‐1 aligned with SERENITY, which observed near‐maximal efficacy at Week 12 with 600–1000 mg mirikizumab IV. Efficacy at Week 52 did not vary markedly with exposure during maintenance. There was no significant association between exposure and adverse events. These results support the selection of 900 mg mirikizumab IV Q4W for induction and 300 mg SC Q4W for maintenance in patients with CD, with no dose adjustment for patient factors required.
format Article
id doaj-art-e785f2c6f55d43c8a8d1d1404e600dfd
institution Kabale University
issn 1752-8054
1752-8062
language English
publishDate 2025-08-01
publisher Wiley
record_format Article
series Clinical and Translational Science
spelling doaj-art-e785f2c6f55d43c8a8d1d1404e600dfd2025-08-23T17:10:42ZengWileyClinical and Translational Science1752-80541752-80622025-08-01188n/an/a10.1111/cts.70320Mirikizumab Pharmacokinetics and Exposure‐Response in Patients With Moderately‐To‐Severely Active Crohn's Disease: Results From Two Randomized StudiesLaiyi Chua0Yuki Otani1Zhantao Lin2Stuart Friedrich3Frederick Durand4Xin Cindy Zhang5Eli Lilly Singapore SingaporeEli Lilly and Company Indianapolis Indiana USAEli Lilly and Company Indianapolis Indiana USAEli Lilly and Company Indianapolis Indiana USAEli Lilly and Company Indianapolis Indiana USAEli Lilly and Company Indianapolis Indiana USAABSTRACT Mirikizumab is a humanized anti–interleukin‐23‐p19 monoclonal antibody approved for both moderately‐to‐severely active ulcerative colitis and moderately‐to‐severely active Crohn's disease (CD). We characterized pharmacokinetics (PK) and exposure‐response (ER) of mirikizumab in relation to efficacy and safety in CD using data from randomized phase 2 SERENITY (NCT02891226) and phase 3 VIVID‐1 (NCT03926130) trials. Patients received 12‐week mirikizumab induction (200, 600, or 1000 mg [SERENITY] or 900 mg [VIVID‐1] intravenously [IV]) or placebo, every 4 weeks (Q4W), then maintenance (200, 600, or 1000 mg IV [SERENITY], 300 mg subcutaneously (SC) [SERENITY and VIVID‐1], or placebo, Q4W) to Week 52. PK and ER for efficacy were analyzed using population PK and logistic regression models for Weeks 12 and 52 endpoints, respectively, and included analyses of covariate effects. Mirikizumab PK was best described by a two‐compartment model, with first‐order absorption for SC maintenance doses. Body weight, body mass index, serum albumin concentration, C‐reactive protein, and disease severity had statistically significant effects on PK, while body weight and disease severity affected ER; these effects were not considered clinically relevant. Efficacy results of 900 mg mirikizumab in VIVID‐1 aligned with SERENITY, which observed near‐maximal efficacy at Week 12 with 600–1000 mg mirikizumab IV. Efficacy at Week 52 did not vary markedly with exposure during maintenance. There was no significant association between exposure and adverse events. These results support the selection of 900 mg mirikizumab IV Q4W for induction and 300 mg SC Q4W for maintenance in patients with CD, with no dose adjustment for patient factors required.https://doi.org/10.1111/cts.70320Crohn's diseaseexposure‐efficacyexposure‐responseexposure‐safetyinterleukin‐23mirikizumab
spellingShingle Laiyi Chua
Yuki Otani
Zhantao Lin
Stuart Friedrich
Frederick Durand
Xin Cindy Zhang
Mirikizumab Pharmacokinetics and Exposure‐Response in Patients With Moderately‐To‐Severely Active Crohn's Disease: Results From Two Randomized Studies
Clinical and Translational Science
Crohn's disease
exposure‐efficacy
exposure‐response
exposure‐safety
interleukin‐23
mirikizumab
title Mirikizumab Pharmacokinetics and Exposure‐Response in Patients With Moderately‐To‐Severely Active Crohn's Disease: Results From Two Randomized Studies
title_full Mirikizumab Pharmacokinetics and Exposure‐Response in Patients With Moderately‐To‐Severely Active Crohn's Disease: Results From Two Randomized Studies
title_fullStr Mirikizumab Pharmacokinetics and Exposure‐Response in Patients With Moderately‐To‐Severely Active Crohn's Disease: Results From Two Randomized Studies
title_full_unstemmed Mirikizumab Pharmacokinetics and Exposure‐Response in Patients With Moderately‐To‐Severely Active Crohn's Disease: Results From Two Randomized Studies
title_short Mirikizumab Pharmacokinetics and Exposure‐Response in Patients With Moderately‐To‐Severely Active Crohn's Disease: Results From Two Randomized Studies
title_sort mirikizumab pharmacokinetics and exposure response in patients with moderately to severely active crohn s disease results from two randomized studies
topic Crohn's disease
exposure‐efficacy
exposure‐response
exposure‐safety
interleukin‐23
mirikizumab
url https://doi.org/10.1111/cts.70320
work_keys_str_mv AT laiyichua mirikizumabpharmacokineticsandexposureresponseinpatientswithmoderatelytoseverelyactivecrohnsdiseaseresultsfromtworandomizedstudies
AT yukiotani mirikizumabpharmacokineticsandexposureresponseinpatientswithmoderatelytoseverelyactivecrohnsdiseaseresultsfromtworandomizedstudies
AT zhantaolin mirikizumabpharmacokineticsandexposureresponseinpatientswithmoderatelytoseverelyactivecrohnsdiseaseresultsfromtworandomizedstudies
AT stuartfriedrich mirikizumabpharmacokineticsandexposureresponseinpatientswithmoderatelytoseverelyactivecrohnsdiseaseresultsfromtworandomizedstudies
AT frederickdurand mirikizumabpharmacokineticsandexposureresponseinpatientswithmoderatelytoseverelyactivecrohnsdiseaseresultsfromtworandomizedstudies
AT xincindyzhang mirikizumabpharmacokineticsandexposureresponseinpatientswithmoderatelytoseverelyactivecrohnsdiseaseresultsfromtworandomizedstudies